Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand placebo or no treatment (moderate certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
Scheduled PDE5I showed no clear difference in treatment discontinuation compared with on demand PDE5I (low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (long‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand PDE5I (very low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
It is very uncertain whether scheduled PDE5I changes treatment discontinuation compared with on demand placebo or no treatment (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with chronic (≥ 12 months) Peyronie's disease (single plaque)
It is very uncertain whether injectional interferon alpha‐2B changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with chronic Peyronie's disease (plaques without calcification)
It is very uncertain whether injectional nicardipine changes discontinuation from treatment compared with saline (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (not defined)
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (diagnosis of disease: at least 12 months, penile curvature: at least 30 degrees)
The review found no eligible studies for this question.
2 findings from 1 review
Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (stable phase)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)
It is very uncertain whether extracorporeal shock wave treatment (ESWT) changes discontinuation from treatment compared with sham (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques (pain during…
It is very uncertain whether potassium paraaminobenzoate changes discontinuation from treatment compared with placebo (very low certainty).
1 finding from 1 review
Treatment discontinuation · men with Peyronie's disease (diagnosis of disease: varying, penile curvature: at least 30 degrees)
It is very uncertain whether penile traction therapy changes discontinuation from treatment compared with no treatment (short‐term) (very low certainty).
1 finding from 1 review
Treatment discontinuation · post‐prostatectomy erectile dysfunction (short‐term)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found